close التداول ينطوي على مخاطر الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Change languageالعربية
Dashboard

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

LLY

747.85

-0.07%↓

UNH

590.82

-1.04%↓

JNJ

155.2

-0.15%↓

NVO

105.18

+2.52%↑

ABBV

177.14

+3.17%↑

Home・Stock List・CRISPR Therapeutics AG
Search

CRISPR Therapeutics AG

Closed

Sector Healthcare

47.93 3.59

Buy

Price update ٢٢ نوفمبر ٢٠٢٤، ٠٨:٥٩ م UTC

BuySell

Overview

Share price change

24h

Current

Min

47.22

Max

47.98

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+40.08 upside

Dividends

By Dow Jones

Next Earnings

١٩ فبراير ٢٠٢٥

News Sentiment

By Acuity

50%

50%

162 / 392 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

47.25 / 52.52 Support & Resistance

CRISPR Therapeutics AG Chart

Past performance is not a reliable indicator of future results.

Related News

٨ ديسمبر ٢٠٢٣، ٠٨:٥٦ م UTC

Major Market Movers

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

DJ

Read

٢٦ سبتمبر ٢٠٢٤، ٠٤:٠٨ م UTC

Earnings
Acquisitions, Mergers, Takeovers

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

DJ

Read

٢٦ سبتمبر ٢٠٢٤، ٠٢:٢٠ م UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

DJ

Read

١١ أبريل ٢٠٢٤، ٠٢:٤٦ م UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

DJ

Read

٨ ديسمبر ٢٠٢٣، ٠٦:٤٥ م UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

DJ

Read

٨ ديسمبر ٢٠٢٣، ٠٤:٤٥ م UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

DJ

Read

٨ ديسمبر ٢٠٢٣، ٠٤:٢١ م UTC

Top News

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- WSJ

DJ

Read

Peer Comparison

Price change

CRISPR Therapeutics AG Forecast

Price Target

By TipRanks

40.08% upside

12 Months Forecast

Average 67.07 USD  40.08%

High 100 USD

Low 30 USD

Based on 17 Wall Street analysts offering 12 month price targets forCRISPR Therapeutics AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

9

Buy

6

Hold

2

Sell

Based on 17 analysts giving stock ratings to CRISPR Therapeutics AG - Dist in the past 3 months.

Technical Score

By Trading Central

47.25 / 52.52Support & Resistance

Short Term

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Bearish Evidence

Recent bearish events outweigh bullish events.

Long Term

Weak Bearish Evidence

All events are bearish.

Sentiment

By Acuity

162 / 392 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

$

Other stocks from the sector

LLY

Eli Lilly and Co.

747.85

↓-0.07%

UNH

UnitedHealth Group Inc

590.82

↓-1.04%

JNJ

Johnson and Johnson

155.2

↓-0.15%

NVO

Novo Nordisk A-S

105.18

↑ +2.52%

ABBV

AbbVie Inc

177.14

↑ +3.17%